NovAccess Global Inc.
novaccessglobal.comWhat Do They Do?
Develops immunotherapies and biomarkers for brain and other cancers for cancer patients and larger biopharmaceutical companies.
10-K for FY2024, filed Jan 14, 2026NovAccess is a biopharmaceutical company that specializes in the research and development of a new drug to treat brain cancer and other…View ↗
We are developing novel therapies for brain cancer patients in the US and ultimately globally. Our research and development process begins…View ↗
At this stage, we do not generate revenue but once we commercialize our products our customers are expected to be cancer patients and/or…View ↗
Who Are Their Customers?
After commercialization, customers are expected to include cancer patients and larger biopharmaceutical companies that license the products for clinical testing or commercialization.
10-K for FY2024, filed Jan 14, 2026At this stage, we do not generate revenue but once we commercialize our products our customers are expected to be cancer patients and/or…View ↗
How Are They Changing?
Biomarkers added
The older report describes drug-candidate research and trials; the latest also includes biomarker development to predict immunotherapy success and guide which patients receive treatment.
10-K for FY2021, filed Jan 13, 2022 10-K for FY2024, filed Jan 14, 2026
Loading...
